NASDAQ : INMB
INmune Bio Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 1.6 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 49.21M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 42.44M |
| Enterprise Value | 25.43M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 5, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 30.75M |
| Shares Outstanding | 30.75M |
| Shares Change (YoY) | +20.73% |
| Shares Change (QoQ) | +0.50% |
| Owned by Insiders (%) | 9.75% |
| Owned by Institutions (%) | 18.88% |
| Float | 27.75M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.87 |
| P/TBV Ratio | 2.08 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 4.04 |
| Quick Ratio | 3.94 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -74.82% |
| Return on Assets (ROA) | -39.12% |
| Return on Invested Capital (ROIC) | -49.42% |
| Return on Capital Employed (ROCE) | -96.37% |
| Weighted Average Cost of Capital (WACC) | 8.89% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$876,952 |
| Employee Count | 21 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.90 |
| 52-Week Price Change | -22.95% |
| 50-Day Moving Average | 1.98 |
| 200-Day Moving Average | 1.64 |
| Relative Strength Index (RSI) | 32.91 |
| Average Volume (20 Days) | 260,867 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 2.89M |
| Short Previous Month | 2.66M |
| Short % of Shares Out | 9.39% |
| Short % of Float | 10.40% |
| Short Ratio (days to cover) | 7.85 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -20.20M |
| Pretax Income | -18.42M |
| Net Income | -18.42M |
| EBITDA | n/a |
| EBIT | -20.20M |
| Earnings Per Share (EPS) | -$0.69 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 18.41M |
| Total Debt | 1.41M |
| Net Cash | 17.01M |
| Net Cash Per Share | $0.55 |
| Equity (Book Value) | 20.36M |
| Book Value Per Share | 0.74 |
| Working Capital | 17.91M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -14.96M |
| Capital Expenditures | -766,000 |
| Depreciation & Amortization | 202,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -15.73M |
| FCF Per Share | -$0.51 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -20.73% |
| Shareholder Yield | -20.73% |
| Earnings Yield | -50.11% |
| FCF Yield | -37.06% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $7.00 |
| Price Target Difference | 407.25% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | 682.00% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -8.68 |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |